echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > FDA awards Bcl-2 inhibitor APG-2575 fifth orphan drug title for treatment of fyring lymphoma (FL)

    FDA awards Bcl-2 inhibitor APG-2575 fifth orphan drug title for treatment of fyring lymphoma (FL)

    • Last Update: 2021-02-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Fable lymphoma (FL) is a heterogeneic disease and is the second most common subtype of non-Hodgkin's lymphoma (NHL) in the United States, accounting for about 20% of all NHL morbidity.
    FL is defined as the proliferation of B cells at the center of malignant birth.
    that although the treatments currently available have significantly improved the overall survival rate of FL patients, the disease remains incurable.
    most or experience disease progress after initial treatment, after which they experience multiple relapses and require follow-up treatment.
    Although there are a number of treatment options for primary and relapse/refractive FL (r/r FL), there are still unsatisfying medical needs in the FL, especially in patients with high risk of recurrence, histological changes, or insatiability with existing therapies.
    Pharmaceuticals ( FDA ) has awarded its new Bcl-2 inhibitor APG-2575 orphan drug ( ODD ) for the treatment of fable lymphoma ( FL ) , the clinical stage biotechnology company announced today .
    previously, APG-2575 had received ODD for the treatment of Waldenström globulinemia (WM), chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML).
    year, the U.S. Food and Drug Administration (FDA) has awarded 10 ODDs to four drug candidates for Ascentage Pharma, the highest number of biopharmaceutical companies in China.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.